Shou Yao Holdings is a developer of oncology and diabetes drugs. It is a mixed-ownership enterprise jointly owned by municipal and district governments. It is mainly engaged in the research and development of small molecule anti-tumor targeted drugs and new diabetes drugs. and production business.
Capital Pharmaceutical Holdings (Beijing) Co., Ltd. was established on April 19, 2016. It is a mixed-ownership high-tech enterprise with state-owned capital participation at the municipal and district levels. The company is headquartered in Jingyuan Street, Yizhuang Economic and Technological Development Zone, Beijing, and focuses on the research, development and production of innovative drugs with independent intellectual property rights.
The company adheres to the principle of performance and focuses on experience and character, making the impossible possible in the field of innovative drugs. Shoudao Holdings has currently been authorized for more than 100 invention patents around the world, obtained 16 national first-class clinical approvals for new drugs (including cooperative research and development projects), and won 8 major new drug creation projects during the national “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan” item.
Currently, 2 new drugs have entered clinical phase III, 2 new drugs have entered clinical phase II, and 10 new drugs have entered clinical phase I. Creating good drugs and creating a new class of drugs that Chinese patients can afford is the pursuit of the shareholders of Shoudao. Let us roll up our sleeves and work hard to build Shoudao Holdings into an international pharmaceutical company integrating R&D, production and sales within a clear and sustainable mechanism of "responsibility, rights and interests".
Beijing Pharmaceutical Holdings is an innovative small molecule drug company in the clinical research stage. Driven by innovation, it has been focusing on the research and development of anti-tumor and other innovative drugs for the past ten years. Its current R&D pipeline covers non-small cells. Key tumor indications such as lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as other important disease areas such as type 2 diabetes.
Beijing Pharmaceutical Holdings has formed a research center integrating AI drug design, medicinal chemistry, target biology, pharmacology, pharmacodynamics, pharmacokinetics, toxicology, pharmacy, clinical medicine, and translational medicine. The innovative drug R&D system is committed to developing into a comprehensive innovative drug enterprise integrating R&D, production and sales.
The revenue of Capital Pharmaceutical Holdings in 2018, 2019, and 2020 was 19.976 million yuan, 11.5476 million yuan, and 7.0191 million yuan respectively, and the net losses were 21.8153 million yuan, 35.9857 million yuan, and 330 million yuan respectively.